Form 4: Keros Therapeutics Director Alpna Seth Acquires 10,000 Stock Options

Director Alpna Seth acquired 10,000 stock options in Keros Therapeutics, Inc. on May 30, 2024, at an exercise price of $46.31.

Summary

• On May 30, 2024, Alpna Seth, a director of Keros Therapeutics, Inc., acquired 10,000 stock options.
• The exercise price of these options is $46.31.
• The options vest in equal quarterly installments over 12 months, fully vesting by the 2025 annual meeting of stockholders, contingent on continued service.
• Following the transaction, Alpna Seth directly owns 10,000 derivative securities (stock options).

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard disclosure of stock option acquisition. While insider buying can be seen as positive, it's a routine part of executive compensation.

Positives

• A director's acquisition of stock options can be seen as a positive sign, indicating confidence in the company's future performance.

Future Outlook

The vesting schedule indicates a commitment from the director to remain with the company at least until the 2025 annual meeting of stockholders.

Industry Context

Form 4 filings are routine disclosures required by the SEC to provide transparency into insider transactions. This filing indicates a director's acquisition of stock options, which is a common form of executive compensation.

Stakeholder Impact

• The acquisition of stock options by a director could be viewed positively by shareholders, as it aligns the director's interests with the company's performance.

Key Dates